Lumilin Therapeutics

Type 1 Diabetes (T1D) is an autoimmune disorder that prevents the pancreas from producing insulin, a hormone that regulates blood glucose levels. In the United States alone, around 1.5 million people live with T1D, and 64,000 more people are diagnosed with T1D each year. At Lumilin Therapeutics, we are developing a fully automated, closed-loop system that closely mimics the function of a healthy pancreas. For patients living with T1D, this system eliminates the need for user intervention, mitigates the risk of long-term complications, and makes management of T1D more convenient. Compared to existing solutions for T1D, our system also decreases patients’ dependencies on drugs such as immunosuppressants, artificial insulin, and/or oral medications. We are a passionate team of engineers and entrepreneurship students, and we are looking for mentors with knowledge of the FDA regulatory process as well as financing for pre-clinical testing.